Company Overview and News

 
AeroVironment upgraded to buy from hold at Stifel Nicolaus

2018-04-11 marketwatch
Shares of drone maker AeroVironment Inc. fell more than 8% late Tuesday after the company swung to a surprise fiscal 2018 third-quarter loss. AeroVironment said it lost $800,000, or 4 cents a share, in the third quarter of fiscal 2018, compared with a net loss of $2.2 million, or 9 cents a share, in the year-ago period. Revenue rose 20% to $64 million, compared with $53.2 million a year ago. Analysts polled by FactSet had expected earnings of 2 cents a share on sales of $63 million.

 
Earnings Review and Free Research Report: Anixter’s Quarterly Sales Grew 3.1%

2017-11-08 accesswire
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Anixter International Inc. (NYSE: AXE) ("Anixter"), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AXE, following the Company's announcement of its third quarter fiscal 2017 operating results on October 24, 2017. The maker of security products, wires, and fasteners missed top- and bottom-line expectations, while it also provided organic sales outlook for the upcoming quarter and the full year.

 
AeroVironment: Post-Earnings Gains Get To (Or Past) Fair Value

2017-07-24 seekingalpha
The market didn't trust that AeroVironment would hit its FY17 guidance after the first half - but it managed to do so.

 
AeroVironment's (AVAV) CEO Wahid Nawabi on Q4 2017 Results - Earnings Call Transcript

2017-06-28 seekingalpha
Good day, ladies and gentlemen. Welcome to the AeroVironment Incorporated Fourth Quarter and Full Fiscal 2017 Earnings Call. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session after management’s remarks. As a reminder, this conference is being recorded for replay purposes.

 
Transurban's tunnel will cut city-western suburbs commute by just eight minutes

2017-05-29 smh.com.au
Motorists travelling between Melbourne's outer west and the CBD can expect to save eight minutes each way off their peak-hour commute by taking Transurban's $5.5 billion West Gate Tunnel, a government report shows.

 
Final Results

2017-03-06 londonstockexchange
Harworth Group plc ("Harworth" or the "Group"), the brownfield regeneration and property investment specialist, announces its preliminary results for the year ended 31 December 2016.

 
Hundreds of St Kilda Road trees to get the chop as part of Metro tunnel project

2016-06-25 smh.com.au
St Kilda Road residents are concerned that hundreds of elm and plane trees planted in the 1890s are about to be destroyed along St Kilda Road to make way for the Melbourne Metro Rail. Photo: Penny Stephens

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...